• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Alpha Teknova Inc.

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TKNO alert in real time by email
    SC 13D 1 d844536dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    ALPHA TEKNOVA, INC.

    (Name of Issuer)

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

    02080L102

    (CUSIP Number)

    Jeanette Welsh

    Chief Financial Officer

    Telegraph Hill Partners

    300 Montgomery Street, Ste 1130

    San Francisco, CA 94104

    (415) 765-6987

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 12, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO: 02080L102       Page 2 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    Telegraph Hill Partners IV, L.P.

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    25,620,792 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    25,620,792 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    25,620,792 (1)

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    48.1%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 3 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    THP IV Affiliates Fund, LLC

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    25,620,792 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    25,620,792 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    25,620,792

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    48.1%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 4 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    Telegraph Hill Partners IV Investment Management, LLC

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    25,620,792 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    25,620,792 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    25,620,792

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    48.1%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 5 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    Telegraph Hill Partners V, L.P.

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    12,096,773 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    12,096,773 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,096,773

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    22.7%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    Includes (i) 11,126,929 shares of common stock held by Telegraph Hill Partners V, L.P. and (ii) 969,844 shares of common stock held by THP V Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 6 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    THP V Affiliates Fund, LLC

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e).

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    12,096,773 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    12,096,773 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,096,773

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    22.7%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    Includes (i) 11,126,929 shares of common stock held by Telegraph Hill Partners V, L.P. and (ii) 969,844 shares of common stock held by THP V Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 7 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    Telegraph Hill Partners V Investment Management, LLC

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    12,096,773 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    12,096,773 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,096,773

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    22.7%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    Includes (i) 11,126,929 shares of common stock held by Telegraph Hill Partners V, L.P. and (ii) 969,844 shares of common stock held by THP V Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 8 of 14

     

     1.   

    NAMES OF REPORTING PERSONS

     

    Telegraph Hill Partners Management Company, LLC

     2.   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3.   

    SEC USE ONLY

     

     4.   

    SOURCE OF FUNDS

     

    OO

     5.   

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     6.   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

        7.   

    SOLE VOTING POWER

     

    0

        8.   

    SHARED VOTING POWER

     

    37,717,565 shares of Common Stock

        9.   

    SOLE DISPOSITIVE POWER

     

    0

       10.   

    SHARED DISPOSITIVE POWER

     

    37,717,565 shares of Common Stock

    11.   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    37,717,565

    12.   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13.   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    70.8%(2)

    14.   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC, (iii) 11,126,929 shares of common stock held by Telegraph Hill Partners V, L.P. and (iv) 969,844 shares of common stock held by THP V Affiliates Fund, LLC.

    (2)

    Consists of 53,301,214 shares of Common Stock of the Issuer outstanding on July 15, 2024, which share information was provided to the Reporting Person by the Issuer.


    CUSIP NO: 02080L102       Page 9 of 14

     

    Explanatory Note

    The Reporting Persons (as defined in Item 2 below) previously filed a Schedule 13G on February 14, 2022, which was amended on October 6, 2023 and February 14, 2024, pursuant to Rule 13d-1(d) of the Act. On July 12, 2024, the Reporting Persons acquired beneficial ownership of more than 2% of the outstanding shares of Common Stock within a twelve-month period, and the Reporting Persons are now filing this Schedule 13D.

     

    Item. 1.

    Security and Issuer

    This statement on schedule 13D (the “Statement”) relates to the common stock, par value $0.00001 per share (the “Common Stock”), of Alpha Teknova, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 2290 Bert Drive, Hollister, California 95023. The Issuer’s shares of Common Stock are listed on The Nasdaq Global Market under the ticker symbol “TKNO”.

     

    Item 2.

    Identity and Background

    (a) – (c) This statement is being jointly filed by the following persons (collectively, the “Reporting Persons”):

     

      (i)

    Telegraph Hill Partners IV, L.P., a Delaware limited partnership (“THP IV”)

     

      (ii)

    THP IV Affiliates Fund, LLC, a Delaware limited liability company (“THP IV Affiliates”)

     

      (iii)

    Telegraph Hill Partners IV Investment Management, LLC, a Delaware limited liability company (“THP IV IM”)

     

      (iv)

    Telegraph Hill Partners V, L.P., a Delaware limited partnership (“THP V”)

     

      (v)

    THP V Affiliates Fund, LLC, a Delaware limited liability company (“THP V Affiliates”)

     

      (vi)

    Telegraph Hill Partners V Investment Management, LLC, a Delaware limited liability company (“THP V IM”)

     

      (vii)

    Telegraph Hill Partners Management Company, LLC, a Delaware limited liability company (“THP MC”)

    The address of the principal business and principal office of each of the Reporting Persons is 300 Montgomery Street, Suite 1130, San Francisco, California 94104.

    The principal business of each of THP IV, THP IV Affiliates, THP V and THP V Affiliates is investing in securities. The principal business of each of THP IV IM and THP V IM is, with respect to THP IV IM, serving as the general partner of THP IV and the manager of THP IV Affiliates and, with respect to THP V IM, serving as the general partner of THP V and the manager of THP V Affiliates. The principal business of THP MC is serving as manager of each of THP IV IM and THP V IM.

    (d) – (e) During the last five years, none of the Reporting Persons has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) The jurisdiction of organization of each of the Reporting Persons is set forth in subsection (a) above.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    The source of funds for the purchases of Common Stock reported herein were from general funds available to the Reporting Persons, including capital contributions from their respective investors.


    CUSIP NO: 02080L102       Page 10 of 14

     

    Item 4.

    Purpose of Transaction

    On July 11, 2024, pursuant to a securities purchase agreement (the “Purchase Agreement”) by and among the Issuer and the purchasers thereto (the “Offering”), THP V and THP V Affiliates purchased 12,096,773 shares of the Issuer’s Common Stock. The Offering closed on July 12, 2024. As a result of the closing of the Offering, the Reporting Persons acquired beneficial ownership during the preceding 12 months in excess of 2% of the outstanding shares of Common Stock. The Purchase Agreement is incorporated herein by reference to Exhibit 2 to this Statement, and the description thereof is qualified in its entirety by reference thereto.

    The Reporting Persons acquired the Common Stock reported herein for investment purposes. Consistent with such purposes, the Reporting Persons may engage in communications with, without limitation, one or more stockholders of the Issuer, management of the Issuer, one or more members of the Board, and may make suggestions concerning the Issuer’s operations, prospects, business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the composition of the Board and such other matters as the Reporting Persons may deem relevant to their investment in the Common Stock. The Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, changing their current intentions with respect to any or all matters required to be disclosed in this Statement. Three individuals affiliated with THP MC currently serve as directors of the Issuer and therefore will engage in regular discussions with the Board and management of the Issuer as part of their duties as directors.

    Except as set forth in this Item 4 or Item 6 below, the Reporting Persons have no present plans or proposals that relate to, or that would result in, any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Exchange Act.

     

    Item 5.

    Interest in Securities of the Issuer

    The information set forth in or incorporated by reference in Items 2, 3, 4 and on the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

    (a)—(b) The applicable Reporting Persons may be deemed to beneficially own an aggregate of 1,223,704 Common Shares, including 200 Common Shares held directly by Atlas Fund IV, and, as described in Item 6, call options which are exercisable for an aggregate of 313,164 Common Shares. These Common Shares (including the Common Shares underlying the above-mentioned call options) represent approximately 5.2% of the outstanding Common Shares.

    THP IV has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 25,620,792 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 25,620,792 Common Shares.

    THP IV Affiliates has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 25,620,792 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 25,620,792 Common Shares.

    THP IV IM has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 25,620,792 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 25,620,792 Common Shares.

    THP V has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 12,096,773 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 12,096,773 Common Shares.

    THP V Affiliates has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 12,096,773 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 12,096,773 Common Shares.


    CUSIP NO: 02080L102       Page 11 of 14

     

    THP V IM has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 12,096,773 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 12,096,773 Common Shares.

    THP MC has the sole power to vote or direct the vote of 0 Common Shares; has the shared power to vote or direct the vote of 37,717,565 Common Shares; has the sole power to dispose or direct the disposition of 0 Common Shares; has the shared power to dispose or direct the disposition of 37,717,565 Common Shares.

    To the applicable Reporting Person’s knowledge, none of the persons named in Schedule I hereto, beneficially owns any shares of Common Stock. None of the Reporting Persons has sole dispositive power or sole voting power as to any Shares.

    (c) Except as reported in the Statement, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days.

    (d) Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.

    (e) Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The response to Item 4 of this Schedule 13D is incorporated herein by reference.

    In connection with the Offering, also on July 11, 2024 certain of the Reporting Persons entered into a registration rights agreement (the “Registration Rights Agreement”) with the Issuer. Pursuant to the terms of the Registration Rights Agreement, the Issuer has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) on or before August 26, 2024 to register for resale the shares of Common Stock purchased in the Offering. The Issuer shall use its commercially reasonable efforts to cause the registration statement covering the aforementioned securities to be declared effective as promptly as possible after the filing thereof, but in any event no later than the 90th calendar day following the date of the Registration Rights Agreement (or in the event of a full review by the SEC, the 120th calendar day following the date of the Registration Rights Agreement). Failure by the Issuer to meet the filing deadlines and other requirements set forth in the Registration Rights Agreement may subject the Issuer to certain liquidated damages. The Registration Rights Agreement is incorporated herein by reference to Exhibit 3 to this Statement, and the description thereof is qualified in its entirety by reference thereto.

    In connection with a private placement offering, certain of the Reporting Persons entered into a registration rights agreement (the “2023 Registration Rights Agreement”) with the Issuer, dated September 15, 2023. Pursuant to the terms of the 2023 Registration Rights Agreement, the Issuer has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) on or before October 30, 2023 to register for resale the 8,108,107 shares of Common Stock purchased by the Reporting Persons in the private placement. The Issuer shall use its commercially reasonable efforts to cause the registration statement covering the aforementioned securities to be declared effective as promptly as possible after the filing thereof, but in any event no later than the 90th calendar day following the date of the 2023 Registration Rights Agreement (or in the event of a full review by the SEC, the 120th calendar day following the date of the 2023 Registration Rights Agreement). Failure by the Issuer to meet the filing deadlines and other requirements set forth in the 2023 Registration Rights Agreement may subject the Issuer to certain liquidated damages. The 2023 Registration Rights Agreement is incorporated herein by reference to Exhibit 4 to this Statement, and the description thereof is qualified in its entirety by reference thereto.

    Certain of the Reporting Persons are party to an investors’ rights agreement with the Issuer, dated January 14, 2019, which grants such Reporting Persons certain registration rights in respect of the “registrable securities” held by them. The registration of shares of the Issuer’s common stock pursuant to the exercise of these registration rights


    CUSIP NO: 02080L102       Page 12 of 14

     

    would enable the holders thereof to sell such shares without restriction under the Securities Act when the applicable registration statement is declared effective. Under the investors’ rights agreement, the Issuer will pay all expenses relating to such registrations, including the fees of one counsel for the participating holders, and the holders will pay all underwriting discounts, commissions and stock transfer taxes relating to the sale of their shares. The investors’ rights agreement also includes customary indemnification and procedural terms. The Reporting Persons hold 17,512,685 shares of Common Stock which qualify as “registrable securities” under the investors’ rights agreement. The investors’ rights agreement is incorporated herein by reference to Exhibit 5 to this Statement, and the description thereof is qualified in its entirety by reference thereto.

     

    Item 7.    Materials to Be Filed as Exhibits
    Exhibit 1    Joint Filing Agreement
    Exhibit 2    Form of Securities Purchase Agreement, dated July 11, 2024 (incorporated by reference to Exhibit 10.1 to Alpha Teknova, Inc.’s Current Report on Form 8-K filed with the SEC on July 12, 2024).
    Exhibit 3    Form of Registration Rights Agreement, dated July 11, 2024 (incorporated by reference to Exhibit 10.2 to Alpha Teknova, Inc.’s Current Report on Form 8-K filed with the SEC on July 12, 2024).
    Exhibit 4    Form of Registration Rights Agreement, dated September 15, 2023 (incorporated by reference to Exhibit 10.3 to Alpha Teknova, Inc.’s Current Report on Form 8-K filed with the SEC on September 19, 2023).
    Exhibit 5    Investors’ Rights Agreement, dated as of January 14, 2019, by and among Alpha Teknova, Inc., and certain of its stockholders (incorporated by reference to Exhibit 4.2 to Alpha Teknova, Inc.’s Registration Statement on Form S-1 (File No. 333-256795 filed with the SEC on June 4, 2021).


    CUSIP NO: 02080L102       Page 13 of 14

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 19, 2024      
       

    Telegraph Hill Partners IV, L.P.

     

    By: Telegraph Hill Partners IV Investment Management, LLC

    Its: General Partner

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
       

    THP IV Affiliates Fund, LLC

     

    By: Telegraph Hill Partners IV Investment Management, LLC

    Its: Manager

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
       

    Telegraph Hill Partners IV Investment Management, LLC

     

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
       

    Telegraph Hill Partners V, L.P.

     

    By: Telegraph Hill Partners V Investment Management, LLC

    Its: General Partner

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner


    CUSIP NO: 02080L102       Page 14 of 14

     

       

    THP V Affiliates Fund, LLC

     

    By: Telegraph Hill Partners V Investment Management, LLC

    Its: Manager

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
       

    Telegraph Hill Partners V Investment Management, LLC

     

    By: Telegraph Hill Partners Management Company, LLC

    Its: Manager

        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
        Telegraph Hill Partners Management Company, LLC
        By:   /s/ Jeanette Welsh
          Jeanette Welsh
          Partner
    Get the next $TKNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TKNO

    DatePrice TargetRatingAnalyst
    7/22/2025$8.00Overweight
    Stephens
    2/10/2025$12.00Buy
    Craig Hallum
    3/12/2024Buy → Neutral
    BTIG Research
    7/20/2021Overweight
    Stephens
    7/20/2021$27.00Overweight
    Stephens & Co.
    7/20/2021Outperform
    Cowen & Co.
    7/20/2021$26.00Buy
    BTIG
    More analyst ratings

    $TKNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Alpha Teknova with a new price target

    Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

    7/22/25 7:51:11 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Craig Hallum initiated coverage on Alpha Teknova with a new price target

    Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

    2/10/25 8:24:48 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova downgraded by BTIG Research

    BTIG Research downgraded Alpha Teknova from Buy to Neutral

    3/12/24 7:34:27 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    SEC Filings

    View All

    SEC Form 10-Q filed by Alpha Teknova Inc.

    10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

    8/8/25 4:07:19 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alpha Teknova, Inc. (0001850902) (Filer)

    8/7/25 4:07:41 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Alpha Teknova Inc.

    EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)

    7/17/25 12:15:12 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 9:13:16 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:04 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Demski Martha J sold $40,512 worth of shares (8,000 units at $5.06), decreasing direct ownership by 40% to 12,000 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:59:45 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Vos Alexander

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Robertson Brett

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:06 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Financials

    Live finance-specific insights

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Leadership Updates

    Live Leadership Updates

    View All

    Teknova Announces New Board Member, Martha J. Demski

    HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

    8/16/23 8:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alpha Teknova Inc.

    SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    10/6/23 4:10:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care